SPOTLIGHT: Cell Therapeutics buys cancer drug
Free newsletter via e-mail
Tools
Cell Therapeutics has agreed to shell out $10 million up front and up to $20 million in milestones for the marketing and development rights of Biogen Idec's Zevalin, a cancer drug. The milestones kick in with the drug's approval as a first-line treatment for non-Hodgkin's lymphoma. Release
More stories about sales and marketing non-Hodgkin's lymphoma milestones Biogen Idec Cancer Drugs lymphoma Cell Therapeutics
SHARE
WITH: